Efficacy and Tolerability of Peginterferonα-2a and Peginterferonα-2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials
Open Access
- 1 January 2013
- journal article
- review article
- Published by Wiley in Gastroenterology Research and Practice
- Vol. 2013, 1-11
Abstract
Background. The efficacy and tolerability of peginterferonα-2a and peginterferonα-2b in chronic hepatitis C (CHC) patients remain controversial.Methods. PubMed, Ovid, and Cochrane libraries were electronically searched until August 30, 2012. Studies that met the inclusion criteria were systematically evaluated by two reviewers independently.Results. The overall sustained virologic response (SVR) rate of the peginterferonα-2a group was significantly higher than that of the peginterferonα-2b group (46.7% versus 42.4%,value = 0.01). The same tendency was observed for naïve, genotype 1/4, and genotype 2/3 patients. The early virologic response (EVR) and end-of-treatment response (ETR) rates were significantly higher in the peginterferonα-2a group than in the peginterferonα-2b group (56.1% versus 49.8%,; 67.9% versus 56.6%,, resp.). Peginterferonα-2a had a significantly lower discontinuation rate than peginterferonα-2b (27.9% versus 33.9%,) in naïve patients. In both naïve CHC and hepatitis C virus genotype 1 patients, peginterferonα-2a had a higher relapse rate than peginterferonα-2b.Conclusions. Peginterferonα-2a has superior efficacy with higher EVR, ETR, and SVR than peginterferonα-2b for CHC patients, both plus ribavirin. Peginterferonα-2a might obtain a similar or even lower discontinuation rate than peginterferonα-2b. However, peginterferonα-2a had a higher relapse rate than peginterferonα-2b.
Keywords
Funding Information
- Shanghai Science and Technology Commission (25382, 20114y020, 10F115)
- Shanghai Municipal Health Bureau (25382, 20114y020, 10F115)
- Fundamental Research Funds for the Central Universities (25382, 20114y020, 10F115)
This publication has 34 references indexed in Scilit:
- Peginterferon Alfa-2a Is Superior to Peginterferon Alfa-2b in the Treatment of Naïve Patients with Hepatitis C Virus Infection: Meta-Analysis of Randomized Controlled TrialsDigestive Diseases and Sciences, 2011
- Pegylated Interferons for the Treatment of Chronic Hepatitis CDrugs, 2010
- Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C InfectionNew England Journal of Medicine, 2009
- Ribavirin dose reduction raises relapse rate dose‐dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha‐2b plus ribavirinJournal of Viral Hepatitis, 2009
- Diagnosis, management, and treatment of hepatitis C: An update # † ‡Hepatology, 2009
- Randomized trial comparing pegylated interferon α‐2b versus pegylated interferon α‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients†Hepatology, 2009
- Long-term outcome of human leukocyte antigen mismatching in liver transplantation: Results of the national institute of diabetes and digestive and kidney diseases liver transplantation databaseHepatology, 2008
- Early and Sustained Virological Response in Non-Responders with Chronic Hepatitis CDrugs, 2008
- A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE)Journal of Hepatology, 2006
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002